Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valbenazine for Dyskinesia Due to Cerebral Palsy
2022-502713-29-00Phase 3Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Mar 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in dyskinetic cerebral palsy (DCP) comparing Valbenazine with Placebo (2 arms). Primary endpoint: Change in UHDRS Total Maximal Chorea (TMC) score. Started Mar 2024; status: completed.
02
Drugs
valbenazine
03
Conditions
dyskinetic cerebral palsy (DCP)
Beyond the preview
Go deeper on 2022-502713-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502713-29-00.